Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziresovir in hospitalized infants with RSV infection
NCT02654171Phase 2Completed
- Sponsor
- Ark Biosciences
- Start
- May 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of ziresovir in respiratory syncytial virus infection (RSV), sponsored by Ark Biosciences. Started May 2016; status: completed.
02
Drugs
ziresovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02654171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654171.